Cargando…
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
The current 2019 novel coronavirus disease (COVID-19), an emerging infectious disease, is undoubtedly the most challenging pandemic in the 21st century. A total of 92,977,768 confirmed cases of COVID-19 and 1,991,289 deaths were reported globally up to January 14, 2021. COVID-19 also affects people’...
Autor principal: | Pashaei, Yaser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973060/ https://www.ncbi.nlm.nih.gov/pubmed/33992179 http://dx.doi.org/10.1016/j.jocn.2021.03.010 |
Ejemplares similares
-
Repurposing Selective Serotonin Reuptake Inhibitors for COVID-19: Rationale and Concerns
por: Navin, Karthick, et al.
Publicado: (2020) -
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
por: Asadi Anar, Mahsa, et al.
Publicado: (2022) -
Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
por: Strawn, Jeffrey R., et al.
Publicado: (2021) -
RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS
por: Singh, A.N., et al.
Publicado: (2000) -
Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition
por: Westin, Andreas Austgulen, et al.
Publicado: (2017)